← Back to Clinical Trials
Recruiting Phase 1 NCT05003388
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for MS
Trial Parameters
Condition Multiple Sclerosis
Sponsor The Foundation for Orthopaedics and Regenerative Medicine
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 15
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2021-06-26
Completion 2025-10
Interventions
AlloRx
Brief Summary
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of multiple sclerosis
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Multiple Sclerosis * Understanding and willingness to sign a written informed consent document Exclusion Criteria: * Active infection * Active cancer * Chronic multisystem organ failure * Pregnancy * Clinically significant abnormalities on pre-treatment laboratory evaluation * Medical condition that would (based on the opinion of the investigator) compromise patient's safety. * Continued drug abuse * Pre-menopausal women not using contraception * Previous organ transplant * Hypersensitivity to sulfur
Related Trials
NCT07225361
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
View Trial →
NCT05003388
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusio
View Trial →
NCT03850301
Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target
View Trial →